Navigation Links
Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
Date:9/25/2007

STOUGHTON, Mass., Sept. 25 /PRNewswire/ -- Cardiosolutions, Inc. (http://www.cardiosolutionsinc.com) has closed a $7 million Series A Convertible Preferred Stock financing led by BioVentures Investors, the company announced today. Cardiosolutions is developing a proprietary, minimally invasive system for repair of a regurgitant mitral valve interfering with normal heart function. The financing will fund pilot human trials of the technology, expected in 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070925/NETU085LOGO )

Mitral regurgitation is the most common type of heart valve insufficiency. It is a long-term disorder in which the valve that separates the left upper chamber of the heart (atrium) from the left lower chamber (ventricle) does not close properly. Debilitating chronic mitral regurgitation affects approximately 6% of women and 3% of men and currently requires open heart surgery for restoration of valve function.

Cardiosolution's Spacer - Tek Technology(TM) utilizes minimally invasive techniques similar to coronary stenting and mitral valvuloplasty. The Company's Percu - Pro System(TM) measures the pumping chambers of the heart and then delivers a proprietary Mitra - Spacer(TM) to the affected valve through a series of small catheters that are threaded into the blood vessels of the patient's inner thigh. This percuntaneous system is designed to greatly reduce the degree of mitral regurgitation in patients with either functional or degenerative valve disease and may allow patients to avoid open heart surgery, a difficult procedure with far greater risk, an extended period of recovery, and significantly greater cost.

"Completing this round of financing is a significant achievement for us and we are very pleased to have BioVentures Investors join our list of backers," stated Jon Wilson, Chief Operating Officer of Cardiosolutions. "If successful, our system can provide an interim option for patients who are too ill for open heart surgery and ultimately, the system may provide an effective preventative therapy for patients with very early stages of mitral regurgitation." Steve Tallarida, President of Cardiosolutions stated, "We believe the spacer technology is a simple and elegant way to treat mitral regurgitation."

Cardiosolutions, Inc., headquartered in Stoughton, Mass., was incubated and founded in 2006 by STD Med, Inc., a Stoughton-based manufacturer and developer of medical technologies. In addition to Cardiosolutions, other companies that began at STD Med are Angiolink Corporation, Arthrosurface Incorporated, and Spirus Medical, Inc. For more on Cardiosolutions, Inc., visit http://www.cardiosolutionsinc.com.


'/>"/>
SOURCE Cardiosolutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy raises $223 million in IPO
2. Fusion 2007: CA chief says IT complexity raises risk
3. Inline intellectual property raises legal issues
4. Biotech with Madison ties raises $21M in capital
5. ConjuGon raises $3.3 million to fund clinical trials
6. Nerites raises $1 million to improve medical tech
7. Brady Corp. raises $137 million in public offering
8. aOva Technologies raises $3 million
9. Bush praises Johnson Controls battery tech in Milwaukee visit
10. Anthropology professors blog raises public interest
11. Mithridion raises $1.6M through angel networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... has an active R&D program for the development ... the Group has a unique research and development center in ... developing Bio Control products. Stockton has ... and regulatory guidelines, and is active in more than 35 ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, ... Education Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen ... Excellence in Education (CEE) will sponsor a Bite of Science professional enrichment session, ...
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... RICHMOND, Calif. , Feb. 4, 2016  Sangamo ... therapeutic genome editing, announced today that Edward Lanphier ... an update on the progress of Sangamo,s ZFP Therapeutic ... company,s business strategy at 2:40 pm ET on Thursday, ... Annual Global Healthcare Conference. The conference is being ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
Breaking Biology News(10 mins):